Abstract

Candida species are considered opportunistic microorganisms present in the normal microbiota of the oral cavity and gastrointestinal and urogenital tracts of human beings. These infections are more common in individuals with compromised immune systems and their frequency has increased over the years. Regarding bioproducts, recent research from natural sources suggest that algae are a promising group in providing new bioactive substances. The objective of this work is to evaluate the antifungal activity and the in vitro modifying potential of the dichloromethane/methanol extract of G. cervicornis against Candida spp. Tests were performed using broth microdilution method to determine the intrinsic activity of the products, and combination therapy with commercial drugs. The intrinsic activity of DMEGC showed fungistatic activity against all Candida species tested at the concentration of 1024 µg/mL. DMEGC at subinhibitory concentrations was able to modify the action of Fluconazole against isolated and standard C. krusei, reducing the amount of drug needed to inhibit the growth of the microorganism by 50% (IC50) by more than 12-fold. The results show that DMEGC can be used to treat C. krusei in combination therapy with commercial antifungals such as Fluconazole. In addition, its fungistatic activity is important to reduce the development of drug resistance. Further studies are needed to verify which compounds isolated from the extract were responsible for its antifungal activity and which mechanisms of action.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call